# Freeline Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/freeline-therapeutics

- Industry: Biotechnology
- Headquarters: Stevenage, UK
- Website: www.freeline.life
- Total disclosed funding: $201M
- Latest round: Series C (Jun 29, 2020)
- Investors on record: 9

## About

Freeline Therapeutics Limited, based in the UK, is a biotechnology firm focused on developing innovative gene therapies aimed at treating chronic and genetic diseases, leveraging advanced techniques to alter disease progression.Freeline Therapeutics Limited, founded in 2015 in Stevenage, UK, specializes in gene therapy to address chronic and genetic conditions. The company has raised a total of USD 28.30 mn, with the latest funding round being a Public to Private round in March 2022, where Syncona Limited sold 24.85 million shares at USD 1.05 each. The current CEO is Michael Parini, while Fran Molloy is noted as the founder, with a history that is not disclosed here. Freeline has completed a total of 9 deals since its inception.Freeline Therapeutics is engaged in the development of gene therapies targeting chronic conditions. Their pipeline includes investigational products like FLT201 for Gaucher disease and a therapy for GBA1-linked Parkinson’s disease. These therapies are designed to change disease progression and are primarily aimed at patients with genetic disorders and neurodegenerative diseases. The company focuses on North America and Europe but plans to expand into more prevalent health issues beyond rare diseases.In 2023, Freeline Therapeutics reported a revenue of USD 621,967.60, with an EBITDA of USD -51,368,112.30, reflecting their ongoing investment in research and development and partnerships within the biotechnology sector.Freeline Therapeutics plans to launch new products in the near future, targeting the expansion of their gene therapy pipeline. The recent funding from the Public to Private deal in March 2022 will support these initiatives, particularly in advancing their existing candidates and exploring new therapeutic options. They aim to enter additional markets beyond North America and Europe, although specific regions have not been detailed.

## Funding rounds

- Series C, Jun 29, 2020, $80M — Novo Holdings, Eventide Asset Management, Wellington Management Company, Acorn Bioventures, Cowen Healthcare Investments, Ample Plus Fund Partnership LTD
- Series C, Dec 19, 2019, $40M — Syncona
- Series B, Jun 18, 2018, $41M — Albion Capital, Syncona
- Series A, Jun 21, 2016, $1.4M — Albion Capital
- Series A, Dec 11, 2015, $38M — UCL Business plc, Syncona

## Investors

- UCL Business plc — Series A
- Syncona (https://capitalatlas.ai/funds/syncona) — Series A, Series B, Series C
- Albion Capital — Series A, Series B
- Novo Holdings — Series C
- Eventide Asset Management (https://capitalatlas.ai/funds/eventide-asset-management) — Series C
- Wellington Management Company — Series C
- Acorn Bioventures (https://capitalatlas.ai/funds/acorn-bioventures) — Series C
- Cowen Healthcare Investments — Series C
- Ample Plus Fund Partnership LTD — Series C